These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 32280709

  • 1. Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.
    Kurtenkov O.
    Biomed Res Int; 2020; 2020():9747040. PubMed ID: 32280709
    [Abstract] [Full Text] [Related]

  • 2. Anti-Thomsen-Friedenreich-Ag (anti-TF-Ag) potential for cancer therapy.
    Almogren A, Abdullah J, Ghapure K, Ferguson K, Glinsky VV, Rittenhouse-Olson K.
    Front Biosci (Schol Ed); 2012 Jan 01; 4(3):840-63. PubMed ID: 22202095
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer.
    Kurtenkov O, Innos K, Sergejev B, Klaamas K.
    Biomed Res Int; 2018 Jan 01; 2018():9579828. PubMed ID: 30105268
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential.
    Kurtenkov O, Izotova J, Klaamas K, Sergeyev B.
    Biomed Res Int; 2014 Jan 01; 2014():830847. PubMed ID: 25276822
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Synthesis and Evaluation of Glycoconjugates Comprising N-Acyl-Modified Thomsen-Friedenreich Antigens as Anticancer Vaccines.
    Sun S, Zheng XJ, Huo CX, Song C, Li Q, Ye XS.
    ChemMedChem; 2016 May 19; 11(10):1090-6. PubMed ID: 27075633
    [Abstract] [Full Text] [Related]

  • 15. Clinical significance of the Thomsen-Friedenreich antigen.
    MacLean GD, Longenecker BM.
    Semin Cancer Biol; 1991 Dec 19; 2(6):433-9. PubMed ID: 1810470
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A tandem enzymatic approach for detecting and imaging tumor-associated Thomsen-Friedenreich antigen disaccharide.
    Li Q, Li Z, Duan X, Yi W.
    J Am Chem Soc; 2014 Sep 10; 136(36):12536-9. PubMed ID: 25157422
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. What controls the expression of the core-1 (Thomsen-Friedenreich) glycotope on tumor cells?
    Karsten U, Goletz S.
    Biochemistry (Mosc); 2015 Jul 10; 80(7):801-7. PubMed ID: 26541995
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.